Sign In
Buy ADMA
$8.69
+0.120 (+1.40%)
At Close: Jun 23, 2026
ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC
11:00am, Monday, 31'st Oct 2022 GlobeNewswire Inc.
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
02:05pm, Thursday, 13'th Oct 2022 Benzinga
Upgrades
TD Securities upgraded the previous rating for BCE Inc (NYSE:BCE) from Hold to Buy. In the second quarter, BCE showed an EPS of $0.68, compared to $0.68 from the year-ago quarter. The current
7 A-Rated Stocks to Buy for Less Than $10
02:25pm, Friday, 23'rd Sep 2022
Some stocks under $10 are cheap for a reason, but there are other stocks under $10 that are solid long-term investments. There are all sorts of equities from which to choose when building your portfol
7 Top-Rated Biotech Stocks to Buy for Q4
03:00pm, Thursday, 15'th Sep 2022
A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.
How to Invest in Meme Penny Stocks in 2022
03:30pm, Sunday, 21'st Aug 2022 PennyStocks
Which meme penny stocks are you buying right now?
The post How to Invest in Meme Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
How to Invest in Meme Penny Stocks in 2022
11:30am, Sunday, 21'st Aug 2022
Which meme penny stocks are you buying right now? The post How to Invest in Meme Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
09:41am, Sunday, 21'st Aug 2022
ADMA Biologics recently reported their Q2 earnings with impressive revenue growth and improved margins. The company is on clear a path toward profitability. The market seems to have identified the opp
Why ADMA Biologics Stock Triumphed on Thursday
10:08pm, Thursday, 11'th Aug 2022 The Motley Fool
Investors were pleasantly surprised by the company's latest set of quarterly figures.
Why ADMA Biologics Stock Triumphed on Thursday
06:08pm, Thursday, 11'th Aug 2022
Investors were pleasantly surprised by the company's latest set of quarterly figures.
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 22.22% and 8.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q2 2022 Results - Earnings Call Transcript
08:39pm, Wednesday, 10'th Aug 2022
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Gr
ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update
08:05pm, Wednesday, 10'th Aug 2022 GlobeNewswire Inc.
2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 10'th Aug 2022
Adma Biologics (ADMA) delivered earnings and revenue surprises of 22.22% and 8.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
09:35pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for
02:00pm, Monday, 08'th Aug 2022 Zacks Investment Research
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
